Nothing Special   »   [go: up one dir, main page]

EP1039903A1 - Il-8 receptor antagonists - Google Patents

Il-8 receptor antagonists

Info

Publication number
EP1039903A1
EP1039903A1 EP99902334A EP99902334A EP1039903A1 EP 1039903 A1 EP1039903 A1 EP 1039903A1 EP 99902334 A EP99902334 A EP 99902334A EP 99902334 A EP99902334 A EP 99902334A EP 1039903 A1 EP1039903 A1 EP 1039903A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
alkyl
4alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99902334A
Other languages
German (de)
French (fr)
Other versions
EP1039903A4 (en
Inventor
Deborah Lynne Bryan
Katherine L. Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1039903A1 publication Critical patent/EP1039903A1/en
Publication of EP1039903A4 publication Critical patent/EP1039903A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • This invention relates to novel benzoisothiazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 and NAP-2 mediated diseases
  • Interleu in-8 Interleu in-8
  • NAP-1 neutrophil attractant activation protein- 1
  • MDNCF monocyte derived neutrophil chemotactic factor
  • NAF neutrophil activating factor
  • Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-l ⁇ , IL-l ⁇ or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP M Baggiolini et al, J Clin Invest 84.
  • GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 also belong to the chemokine ⁇ family Like IL-8 these chemokines have also been referred to by different names For instance GRO ⁇ , ⁇ , ⁇ have been referred to as MGSA ⁇ , ⁇ and ⁇ respectively (Melanoma Growth Stimulating Activity), see Richmond et al, J Cell Physiology 129, 375 (1986) and Chang et al, J Immunol 148, 451 (1992) All of the chemokines of the ⁇ -family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 and ENA-78 stimulate a number of functions in vitro They have all been shown to have chemoattractant properties for neutrophils, while DL-8 and GRO ⁇ have demonstrated T-lymphocytes, and basophiles chemotactic activity
  • IL-8 can induce histamine release from basophils from both normal and atopic individuals
  • GRO- ⁇ and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils
  • IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis This may contribute to increased adhesion of the neutrophils to vascular endothelial cells
  • Many known diseases are characterized by massive neutrophil infiltration As IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the B-receptor Thomas et al , J Biol Chem 266. 14839 (1991), and Holmes et al , Science 253. 1278 (1991)
  • the development of non-peptide small molecule antagonists for members of this receptor family has precedent For a review see R Freidinger in Progress in Drug Research. Vol 40, pp 33-98, Birkhauser Verlag, Basel 1993 Hence, the E -8 receptor represents a promising target for the development of novel anti-inflammatory agents
  • IL-8R ⁇ Two high affinity human IL-8 receptors (77% homology) have been characterized IL-8R ⁇ , which binds only IL-8 with high affinity, and IL-8R ⁇ , which has high affinity for IL-8 as well as for GRO- ⁇ , GRO ⁇ , GRO ⁇ and NAP-2
  • IL-8R ⁇ Two high affinity human IL-8 receptors (77% homology) have been characterized IL-8R ⁇ , which binds only IL-8 with high affinity
  • IL-8R ⁇ which has high affinity for IL-8 as well as for GRO- ⁇ , GRO ⁇ , GRO ⁇ and NAP-2
  • This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 ⁇ or ⁇ receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemokine is IL-8.
  • This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • the present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutical carrier or diluent.
  • A is CR 20 R2i
  • Z is W, optionally substituted heteroaryl, optionally substituted C5_g cycloalkyl, optionally substituted C J .
  • I Q alkyl optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl; n is an integer having a value of 1 to 3; m is an integer having a value of 1 or 3 ; q is 0, or an integer having a value of 1 to 10; s is an integer having a value of 1 to 3; t is 0, or an integer having a value of 1 or 2; v is 0, or an integer having a value of 1 to 4; Ri is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, C i-io alkoxy, halosubstituted Ci-io alkoxy, (CRgRg)q S(0) t R4, hydroxy, hydroxy
  • Ri moieties together may form O-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted;
  • R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci -4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i-4alkyl, heterocyclic, heterocyclic C 1 _4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O N/S;
  • R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
  • R 8 is independently hydrogen or C i-4 alkyl
  • RlO is C 1-10 alkyl C(O)2R8;
  • Rl 1 is hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl
  • Rl2 is hydrogen, C i-io alkyl, optionally substituted aryl or optionally substituted aryl alkyl;
  • Rl3 and R14 are independently hydrogen, optionally substituted C i-4 alkyl, or one of R13 and R14 may be an optionally substituted aryl;
  • Rj 5 and Rjg are independently hydrogen, or an optionally substituted C 1.4 alkyl;
  • Rl 7 is C ⁇ _4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC ⁇ _4alkyl, heterocyclic, or heterocyclicC ⁇ _4alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted;
  • i g is NRgR7, alkyl, arylC ⁇ .4 alkyl, arylC2-4 alkenyl, heteroaryl, heteroaryl-
  • R20 and R21 are independently hydrogen, halogen, cyano, halosubstituted
  • R25 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur;
  • Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C i- i o alkyl, C2-10 alkenyl, C i - io alkoxy, halosubstituted C i-io alkoxy, (CRgRg)q S(O)tR4, hydroxy, hydroxyC 1 -4alkyl, aryl, aryl C i-4 alkyl, aryloxy, arylC i-4 alkyloxy, heteroaryl, heteroaryl C i -4 alkyl, heteroaryl C i-4 alkyloxy, heterocyclic, heterocyclicC 1 -4alkyl, aryl C2- 10 alkenyl, heteroarylC2-10 alkenyl, heterocyclicC2
  • (CR 8 R 8 )qNHS(O) 2 R ⁇ g, or (CRgRg)qS(O) 2 NR 4 R 5 ; or two Y moieties together may form O-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted,
  • the E containing ring is optionally selected from
  • the compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 ⁇ and ⁇ receptors
  • Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section
  • Ri is independently selected from hydrogen, halogen; nitro, cyano, halosubstituted Ci-io alkyl, such as CF3, Ci-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl, C2-10 alkenyl, Ci-io alkoxy, such as methoxy, or ethoxy, halosubstituted C 1.10 alkoxy, such as trifluoromethoxy, azide, (CR 8 R 8 )q S(O)tR4, where
  • s is an integer having a value of 1 to 3
  • q is 0, or an integer having a value of 1 to 10
  • Ri forms a dioxybridge
  • s is preferably 1
  • Ri forms an additional saturated or unsaturated ring, it is preferably 6 membered unsaturated ring resulting in a naphthalene ring system
  • These rings may be optionally substituted independently, 1 to 3 times, by other Ri moieties as defined above
  • R4 and R5 are independently hydrogen, optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C ⁇ _4alkyl, heterocyclic, heterocyclicC 1.4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S
  • R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur
  • Rg is independently hydrogen or C 1.4 alkyl
  • Rio is Ci-io alkyl C(O)2R8, such as CH2C(0)2H or CH 2 C(O) 2 CH 3
  • Rj 1 is hydrogen, C 1.4 alkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroaryl C 1 _4aikyl, heterocyclic, or heterocyclic C 1 _4alkyl
  • R12 is hydrogen, C 1-10 alkyl, optionally substituted aryl or optionally substituted arylalkyl
  • R13 and R14 are independently hydrogen, an optionally substituted Ci-4 alkyl which may be straight or branched as defined herein, or one of R13 and Rl4 are an optionally substituted aryl
  • v is 0, or an integer having a value of 1 to 4
  • R j 3 or R j 4 are an optionally substituted alkyl
  • the alkyl moiety may be substituted one to three times independently by halogen, halosubstituted Ci-4 alkyl such as trifluoromethyl, hydroxy, hydroxy C 1 -4alkyl, C 1.4 alkoxy, such as methoxy, or ethoxy, halosubstituted C i-io alkoxy, S(O)tR4, aryl, NR4R5, NHC(O)R4, C(O)NR4R5, or C(O)ORg
  • R17 is Ci-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclic, or heterocyclicC ⁇ _4alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted
  • Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C i-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR 8 R 8 )q S(O)tR4, hydroxy, hydroxyC ⁇ _4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, arylCi-4 alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl Ci-4 alkyloxy, heterocyclic, heterocyclic C i-4alkyl, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CR 8 Rg)q NR4R5, C2-10 alkenyl C(O)NR4R 5 , (CRgR 8 )q C(O)NR4R5, (CR
  • s is preferably 1
  • Y forms an additional saturated or unsaturated ring it is preferably 6 membered unsaturated ring resulting in a naphthalene ring system
  • These rings may be optionally substituted 1 to 3 times by other Y moieties as defined above
  • Rj is NRgR7, alkyl, aryl C 1.4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C 1 _4alkyl, heteroarylC2_4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted Y is preferably a halogen, C ⁇ .4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or aryl Ci-4 alkoxy, methylenedioxy, NR4R5, thio C 1 -4alkyl, thioaryl, halosubstituted C 1 - 10 alkoxy, optionally substituted C 1 -4 alkyl, or hydroxy Ci-4 alkyl Y is more preferably a mono-substituted halogen, disubstituted halogen, mono-substituted alk
  • Y may be substituted in any of the 5 ring positions when W is a phenyl moiety, Y is preferably mono-substituted in the 2'-position or 3'- position, with the 4'- preferably being unsubstituted If the phenyl ring is disubstituted, the substituents are preferably in the 2' or 3' position of a monocyclic ring While both Rj and Y can both be hydrogen, it is preferred that at least one of the rings be substituted, preferably both rings are substituted
  • A is suitably CR20R21
  • R20 and R21 are independently hydrogen, halogen, cyano, halosubstituted Cl-io alkyl, Cj-io alkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroarylC 1 _4alkyl, heterocyclic, heterocyclic C i-4alkyl, (CRgRg)q OR4, (CRgRg)q C(0)Ri 1, (CRgR 8 )q C(0)ORi2, (CR 8 R 8 )q OC(O) Rl 1, (CR 8 R 8 )q NR4R5, (CR 8 R 8 )q NR4C(O)R ⁇ 1, or (CRgR 8 )q C(O)NR4RJ O, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted, provided that both R20 and R21 are not hydrogen.
  • R15 and R ⁇ are independently hydrogen, or an optionally substituted C1-4 alkyl as defined above for R13 and R14
  • Z is W, optionally substituted heteroaryl, optionally substituted C5_ 8 cycloalkyl, optionally substituted C ⁇ _ ⁇ Q alkyl optionally substituted C2-10 alkenyl, or an optionally substituted C2.10 alkynyl
  • W is , or
  • the E containing ring is optionally selected from
  • (*) may optionally be present If not present the ring is a phenyl moiety which is substituted by the Y terms as shown
  • the E ring may be substituted by a (Y) n moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated ring(s)
  • the ring may be substituted by (Y) n as defined above
  • Z is an optionally substituted C ⁇ _jo alkyl an optionally substituted C2_ ⁇ o alkenyl, or an optionally substituted C2-10 alkynyl
  • these moieties may be optionally substituted one or more times independently by halogen, nitro, cyano, halosubstituted Ci-io alkyl, such as trifluoromethyl, C i-io alkoxy, halosubstituted Ci-io alkoxy, S(O)tR4, hydroxy, hydroxy C i-4alkyl, aryloxy, arylC ⁇ .4 alkyloxy; heteroaryloxy, heteroaryl C 1.4 alkyloxy, heterocyclic, heterocyclic C 1 -4alkyl, heterocyclicoxy, heterocyclic C 1.4 alkyloxy, NR4R5, C(O)NR4Rs, C(O)NR4R ⁇ o, S(O)3R8, C(O)R 1 1 , C(0)OR 12, OC
  • Z when Z is an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl these moieties may also, in addition to those moieties noted above, may also be optionally substituted with aryl, aryl C 1.4 alkyl, heteroaryl, and heteroaryl C ] -4 alkyl
  • Z when Z is a heteroaryl (HET) ring, it is suitably a heteroaryl ⁇ ng or ⁇ ng system
  • the HET moiety is a multi ring system, the ⁇ ng containing the heteroatom does not need to be directly attached to the urea moiety All the rings in this ring system may be optionally substituted as defined herein
  • the HET moiety is a py ⁇ dyl, which may be 2-, 3- or 4-py ⁇ dyl If the ring is a multi system ⁇ ng it is preferably benzimidazole, dibenzothiophene, or an indole ⁇ ng Other heterocycl
  • the HET ring may be optionally substituted independently one to three times by Y n ) as defined above
  • R j is NR R7, alkyl, arvlC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C ⁇ _4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the alkyl, aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted as defined herein
  • X is suitably cyano, ORi j, C(O)NR24R25, R 23 , C(0)Rj !, C(0)OR ⁇ h or S(O) 2 R 2 2
  • R22 is Ci-4 alkyl, NR15R16, OR] ], optionally substituted aryl, optionally substituted aryl C 1 -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl
  • R23 is optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl
  • R24 and R25 are independently hydrogen, optionally substituted C i- 4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC 1 -4alkyl, or R24 and
  • R25 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur.
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy hydroxy substituted Ci-ioalkyl
  • Ci-io alkoxy such as methoxy or ethoxy
  • S(0)m' Ci-io alkyl wherein m 1 is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl
  • amino, mono & di-substituted amino such as in the NR4R5 group; NHC(O)R4; C(O)N 4R5; C(O)OH; S(O)2NR4R5; NHS(O)2Rl9
  • Ci-io alkyl such as methyl, ethyl, propyl, isopropyl, or t-butyl
  • halosubstituted Cl-10 alkyl such CF3
  • an optionally substituted ary substituted alkyl such as methyl, ethyl, propyl
  • Ci-io alkyl amino, mono & di-substituted amino, such as in the NR4R5 group
  • Ci-io alkyl or halosubstituted Ci-io alkyl, such as CF3.
  • Rl9 is suitably Ci-4 alkyl, aryl, aryl Ci-4alkyl, heteroaryl, heteroarylC 1 _4alkyl, heterocyclic, or heterocyclicC 1 -4alkyl.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
  • pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. The following terms, as used herein, refer to:
  • halo all halogens, that is chloro, fluoro, bromo and iodo.
  • cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl and the like.
  • heteroaryl (on its own or in any combination, such as “heteroaryloxy”, or “heteroaryl alkyl”) - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
  • heterocyclic (on its own or in any combination, such as “heterocyclicalkyl”) - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
  • Exemplified compounds of Formula (I) include: N-[4-Chloro-(l,3)-dihydro-2,2-dioxo-2, l-benzisothiazo-7-yl]-N'-[2- bromophenyl] -N"-cyanoguanidine
  • the compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below.
  • the synthesis provided for in these Schemes is applicable for the producing of Formula (I) having a variety of different Z, R ⁇ , and E' groups which are reacted, employing optional substituents which are suitably protected to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed.
  • further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art. While the schemes are shown with various compounds of Formula (I) this is merely for illustration purposes only and not a limitation on the extent of synthesis available using these methods.
  • the commercially available 2,6-dichlorobenzylbromide can be treated with potassium thioacetate to form the thioacetate, followed by oxidation using chlorine gas in ACOH/H2O to form the sulfonyl chloride (3, Scheme 1).
  • the sulfonyl chloride can be converted to the corresponding sulfonamide (4, Scheme 1) by using NH4OH followed by acidification.
  • the cyclic sulfonamide (5, Scheme 1) can be cyclized under basic conditions such as potassium carbonate using copper as catalyst followed by acidification.
  • Cyclic sulfonamide ( ⁇ ⁇ Scheme 2) can be prepared by protection of the nitrogen using allyl bromide, followed by alkylation of the methylene with alkyl halide in the presence of a strong base such as sodium hexamethyldisilazane.
  • the nitro compound (8, Scheme 2) can be prepared from _7, (Scheme 2) using standard nitration conditions (using NaNO3 or NH4NO3), then reduced to the corresponding aniline (9, Scheme 2) with stannous chloride using standard conditions in a polar solvent such as methanol, ethanol, DMF, or ethyl acetate.
  • R 20 Me
  • H R 21 Me
  • the aniline compound (9, Scheme 2) can be prepared by protection of the nitrogen of J_0 with allyl bromide, followed by alkylation of methylene with alkyl halide and reduction with SnCb in EtOH.
  • Ortho substituted heterocyclic phenyl thioureas Q2, Scheme 4) may be prepared by standard conditions involving the condensation of the commercially available optionally substituted aryl isothiocyanate with the corresponding aniline 9_in an aprotic solvent (such as DMF).
  • the aniline I0_ may be reacted in a 2 step process to form the thioureas 12, by treatment of aniline 10 with thiophosgene to form the isothiocyanate ( ⁇ , Scheme 4) and then reacting this with a commercially available optionally substituted aniline.
  • the carbodiimide may also be prepared by treatment with phosgene and a tertiary amine or by reaction the thiourea J_2 with triphenylphosphine, carbon tetrachloride and triethylamine.
  • suitable substituted guanidines may be prepared as described in PCT application PCT US97/13863, PCT application PCT US97/13864; and PCT application PCT US97/ 13858 whose disclosures are incorporated herein by reference in their entirety.
  • A, Rj, m are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group.
  • Another aspect of the present invention is the chemical intermediate of
  • A, Rj, m are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group.
  • Another aspect of the present invention is a process of making a compound of Formula (1) which process comprises reacting a carbodiimide of the formula O o
  • the compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines which bind to the IL-8 ⁇ or ⁇ receptor, also referred to as the type I or type II receptor
  • the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 ⁇ or ⁇ receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof
  • the chemokines are IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA- 78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state
  • Abnormal levels of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 for instance in the context of the present invention constitute (i) levels of free IL-8 greater than or equal to 1 picogram per mL, (ii) any cell associated IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 above normal physiological levels, or (iii) the presence IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 above basal levels in cells or tissues in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 respectively, is produced There are many disease
  • interleukin-8 and rhinovirus may be found in articles such as Turner, et al , Clin Infect. Dis (1998), 26(4), 840-846, Sanders, et al , J Virol (1998), 72(2), 934-942, Sethi, et al , Clin Exp Immunol (1997), 1 10(3), 362-369, Zhu, et al , Am J Physiol (1997), 273(4, Pt 1), L814-L824, Terajima, et al , Am J Physiol (1997), 273(4, Pt 1), L749-L759, Grunberg, et al , Clin Exp Allergy (1997), 27(1), 36-45, and Johnston, et al .
  • the present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I)
  • CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region Also included within this definition is ischemic stroke, particularly to the brain area
  • Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel
  • embolus a focal neurologic disorder that results from insufficient blood supply to a particular brain area
  • thrombi a progressive neurologic disorder that results from insufficient blood supply to a particular brain area
  • local atheromatous closure of the blood vessel The role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
  • TNF- ⁇ is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression.
  • Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al., Stoke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation.
  • the discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein.
  • the compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.
  • IL-8 mediated disease or disease state refers to any and all disease states in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 plays a role, either by production of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 themselves, or by IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF.
  • a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
  • chemokine mediated disease or disease state refers to any and all disease states in which a chemokine which binds to an IL-8 ⁇ or ⁇ receptor plays a role, such as but not limited IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78. This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF.
  • cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response
  • a cytokine includes, but is not limited to, monokines and lymphokines.
  • a monokine is generally referred to as being produced and secreted bv a mononuclear cell, such as a macrophage and/or monocyte
  • monokines such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B-lymphocytes Lymphokines are generally referred to as being produced by lymphocyte cells
  • cytokines include, but are not limited to, Interleukin- 1 (IL-1), Interleuk ⁇ n-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor beta (TNF- ⁇ )
  • chemokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term “cytokine” above
  • a chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells
  • chemokines include, but are not limited to, IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, IP- 10, MlP-l ⁇ , MlP- ⁇ , PF4, and MCP 1, 2, and 3
  • Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation
  • the compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical earners according to conventional procedures
  • the compounds of Formula (I) may also be administered in conventional dosages m combination with a known, second therapeutically active compound
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25mg to about lg
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • Compounds of Formula (I) may be administered topically, that is by non- systemic administration This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient may comprise, for topical administration, from 0 001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0 1% to 1% w/w of the Formulation
  • Lotions according to the present invention include those suitable for application to the skin or eye
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil, wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof Suspending agents such as natural gums, cellulose derivatives or in
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C for half an hour
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0 002%), benzalkonium chloride (0 01%) and chlorhexidine acetate (0 01%)
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol
  • Compounds of formula (I) may be administered parenterally
  • Appropnate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques
  • the daily oral dosage regimen will preferably be from about 0 01 to about 80 mg/kg of total body weight
  • the daily parenteral dosage regimen about 0 001 to about 80 mg/kg of total body weight
  • the daily topical dosage regimen will preferably be from 0 1 mg to 150 mg, administered one to four, preferably two or three times daily
  • the daily inhalation dosage regimen will preferably be from about 0 01 mg/kg to about 1 mg/kg per day
  • the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques
  • the optimal course of treatment, i e the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined
  • BIOLOGICAL EXAMPLES The EL-8, and GRO- ⁇ chemokine inhibitory effects of compounds of the present invention are determined by the following /// vitro assay
  • [I2 iL_ 8 (human recombinant) is obtained from Amersham Corp , Arlington Heights, IL, with specific activity 2000 Ci/mmol GRO- ⁇ is obtained from NEN- New England Nuclear All other chemicals are of analytical grade High levels of recombinant human IL-8 type ⁇ and ⁇ receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, et al..
  • IL_ 8 (o 25 nM) or 125] Gro- ⁇ and 0 5 ⁇ g/mL of IL-8R ⁇ or 1 0 ⁇ g/mL of IL-8R ⁇ membranes in 20 mM Bis-Trispropane and 0 4 mM Tris HC1 buffers, pH 8 0, containing 1 2 mM MgSO4, 0 1 mM EDTA 25 mM NaCl and 0 03% CHAPS
  • drug or compound of interest is added which has been pre-dissolved in DMSO so as to reach a final concentration of between 0 OlnM and 100 uM
  • the assay is initiated by addition of ⁇ l-JL-S After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethylenimine/0 5% BSA and washed 3 times with 25 mM NaCl,
  • the in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol. I, Suppl 1, Unit 6.12.3 , whose disclosure is incorporated herein by reference in its entirety Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1, whose disclosure is incorporated herein by reference in its entirety
  • the chemoattractants IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0 1 and 100 nM.
  • the two chambers are separated by a 5um polycarbonate filter
  • compounds of this invention are tested, they are mixed with the cells (0 001 - 1000 nM) just prior to the addition of the cells to the upper chamber Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5% CO2.
  • the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA) Cells which have chemotaxed to the chemokine are visually counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated.
  • the compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils.
  • Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1.
  • PMNs 0.88 x 10 6 cells suspended in Ringer's Solution (NaCl 1 18, KC1 4.56, NaHC03 25, KH2PO4 1.03, Glucose 1 1.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 ul.
  • test compound 0.001 - 1000 nM
  • Cytochalasin B in a volume of 50 ul (20ug/ml)
  • Ringers buffer in a volume of 50 ul.
  • These cells are allowed to warm (37 °C, 5% CO2, 95% RH) for 5 min. before IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2 at a final concentration of 0.01 - 1000 nM was added.
  • the reaction is allowed to proceed for 45 min. before the 96 well plate is centrifuged (800 xg 5 min.) and 100 ul of the supernatant removed.
  • This supernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline. Immediately, the plate is placed in a fluorescent 96 well plate reader
  • This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- ⁇ is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- ⁇ plays an important role in both the acute and regenerative response to CNS trauma.
  • a suitable assay may be found in WO 97/35856 or WO 97/49286 whose disclosures are incorporated herein by reference.
  • This assay characterizes the regional expression of interleukin- 1 ⁇ (IL-l ⁇ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-l ⁇ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-l ⁇ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury.
  • TBI lateral fluid-percussion traumatic brain injury
  • the hearts are bisected just below the level of the atria and the base of the heart plus aortic root are taken for analysis. After equilibrating the tissue in OCT compound overnight the hearts are immersed in OCT compound on a cryostat chuck (Bright Instrument Company Ltd. , UK) with the aorta facing the chuck. The tissue is frozen by surrounding the chuck with dry ice. The hearts are then sectioned perpendicular to the axis of the aorta, starting within the heart and working in the direction of the aorta. Once the aortic root has been identified by the appearance of the three valve leaflets, alternate 10 mm sections are taken and mounted on gelatinised slides.
  • Sections are air dried for 1 hour and subsequently rinsed briefly in 60% isopropyl alcohol.
  • the sections are stained with Oil Red O, counterstained with Mayer's haematoxylin, cover slipped using glycerol gelatine and sealed with nail varnish.
  • Pentium P5-133 Datacell, Berks, U.K.
  • a framegrabbing board Tinapper
  • Colour thresholds are set that quantify the areas that are stained red within the lesions.
  • Absolute values for the cross-sectional areas of the lesions and the areas stained red are obtained by calibrating the software using an image of the grid on a haemocytometer slide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

This invention relates to novel compounds of Formula (I), and compositions therof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Description

IL-8 RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention relates to novel benzoisothiazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ, ENA-78 and NAP-2 mediated diseases
BACKGROUND OF THE INVENTION
Many different names have been applied to Interleu in-8 (IL-8), such as neutrophil attractant activation protein- 1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-lα, IL-lβ or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP M Baggiolini et al, J Clin Invest 84. 1045 (1989), J Schroder et al, J Immunol 139. 3474 (1987) and J Immunol 144. 2223 (1990) , Stricter, et al, Science 243. 1467 (1989) and J Biol Chem 264. 10621 (1989), Cassatella et al, J Immunol 148, 3216 (1992)
GROα, GROβ, GROγ and NAP-2 also belong to the chemokine α family Like IL-8 these chemokines have also been referred to by different names For instance GROα, β, γ have been referred to as MGSAα, β and γ respectively (Melanoma Growth Stimulating Activity), see Richmond et al, J Cell Physiology 129, 375 (1986) and Chang et al, J Immunol 148, 451 (1992) All of the chemokines of the α-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor
IL-8, GROα, GROβ, GROγ, NAP-2 and ENA-78 stimulate a number of functions in vitro They have all been shown to have chemoattractant properties for neutrophils, while DL-8 and GROα have demonstrated T-lymphocytes, and basophiles chemotactic activity In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO-α and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis This may contribute to increased adhesion of the neutrophils to vascular endothelial cells Many known diseases are characterized by massive neutrophil infiltration As IL-8, GROα, GROβ, GROγ and NAP-2 promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al, FEBS Lett 307. 97 (1992), Miller et al, Crit Rev Immunol 12, 17 (1992), Oppenheim et al, Annu Rev Immunol 9. 617 (1991), Seitz et al , J Clin Invest 87. 463 (1991). Miller et al . Am. Rev Respir Pis 146. 427 (1992). Donnelv et al . Lancet 341. 643 (1993) In addition the ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis Strieter et al, Science 258, 1798 (1992)
In vitro, IL-8, GROα, GROβ, GROγ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the B-receptor Thomas et al , J Biol Chem 266. 14839 (1991), and Holmes et al , Science 253. 1278 (1991) The development of non-peptide small molecule antagonists for members of this receptor family has precedent For a review see R Freidinger in Progress in Drug Research. Vol 40, pp 33-98, Birkhauser Verlag, Basel 1993 Hence, the E -8 receptor represents a promising target for the development of novel anti-inflammatory agents
Two high affinity human IL-8 receptors (77% homology) have been characterized IL-8Rα, which binds only IL-8 with high affinity, and IL-8Rβ, which has high affinity for IL-8 as well as for GRO-α, GROβ, GROγ and NAP-2 See Holmes et al , supra; Murphy et al , Science 253, 1280 (1991), Lee et al , J Biol Chem 267, 16283 (1992), LaRosa et al , J Biol Chem 267. 25402 (1992), and Gayle et al , J Biol Chem 268. 7283 (1993)
There remains a need for treatment, in this field, for compounds which are capable of binding to the IL-8 α or β receptor Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-cells subsets into the inflammatory site) would benefit by compounds which are inhibitors of EL-8 receptor binding SUMMARY OF THE INVENTION
This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.
This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I). The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutical carrier or diluent.
Compounds of Formula (I) useful in the present invention are represented by the structure:
0) wherein
A is CR20R2i;
R is NH-C(=N-X)-NH-(CR13R14)V - Z; X is cyano, OR] h C(0)R] ] , C(O)OR! \, S(O)2R22* R23< or C(0)NR24R25.
Z is W, optionally substituted heteroaryl, optionally substituted C5_g cycloalkyl, optionally substituted C J . I Q alkyl, optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl; n is an integer having a value of 1 to 3; m is an integer having a value of 1 or 3 ; q is 0, or an integer having a value of 1 to 10; s is an integer having a value of 1 to 3; t is 0, or an integer having a value of 1 or 2; v is 0, or an integer having a value of 1 to 4; Ri is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, C i-io alkoxy, halosubstituted Ci-io alkoxy, (CRgRg)q S(0)tR4, hydroxy, hydroxy C ]-4alkyl, aryl, aryl C i-4 alkyl, aryloxy, arylC i-4 alkyloxy, heteroaryl, heteroaryl C i-4 alkyl, heterocyclic, heterocyclicC i-4alkyl, heteroarylC ι .4 alkyloxy, arylC2-10 alkenyl, heteroarylC2- 10 alkenyl, heterocyclicC2-10 alkenyl, (CRgRg)qNR4R5, C2-10alkenylC(O)NR4R5, (CRgRg)qC(O)NR4R5, (CRgR )qC(0)NR4Rιo, S(O)3R8, (CR R )q C(0)Rl 1, C2-10 alkenylC(O)Rι 1, C2-10alkenylC(O)ORl l, (CRgRg)q C(O)Ri 1, (CR R8)qC(O)ORι2,
(CRgR8)qOC(O)Rι 1, (CR8Rg)qNR4C(O)Rl 1, (CR8R8)qC(NR4)NR4R5, (CRgRg)q NR4C(NR5)R! (CRgR )q NHS(O)2Rι7, or (CR8R8)q S(O)2NR4R5, or two Ri moieties together may form O-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted;
R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci -4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i-4alkyl, heterocyclic, heterocyclic C 1 _4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O N/S; R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
R8 is independently hydrogen or C i-4 alkyl;
RlO is C 1-10 alkyl C(O)2R8;
Rl 1 is hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl
C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 _4alkyl; Rl2 is hydrogen, C i-io alkyl, optionally substituted aryl or optionally substituted aryl alkyl; Rl3 and R14 are independently hydrogen, optionally substituted C i-4 alkyl, or one of R13 and R14 may be an optionally substituted aryl;
Rj 5 and Rjg are independently hydrogen, or an optionally substituted C 1.4 alkyl; Rl 7 is C ι_4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC ι_4alkyl, heterocyclic, or heterocyclicC ι_4alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted; i g is NRgR7, alkyl, arylC ι.4 alkyl, arylC2-4 alkenyl, heteroaryl, heteroaryl-
C ] _4alkyl, heteroary!C2-4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted; R20 and R21 are independently hydrogen, halogen, cyano, halosubstituted
C i-ioalkyl, C i - i oalkyl, aryl, aryl C i-4 alkyl, heteroaryl; heteroaryl C ]-4 alkyl. heterocyclic, heterocyclic C i-4alkyl, (CR8R8)qOR4, (CRgRg)qC(O)Rι 1,
(CRgR8)qC(0)ORi 2, (CRgRg)qOC(O) Ri 1 , (CRgRg)qNR4R5, (CR8R8)qNR4C(O)Ri 1 , (CRgRg)q C(O)NR4Rl θ; and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted, provided that both R20 and R21 are not hydrogen; R22 is C 1 -4 alkyl, NR^Rj g, OR] \, optionally substituted aryl, optionally substituted aryl C 1 _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 _4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl; R23 is optionally substituted C i -4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 _4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl; R24 and R25 are independently hydrogen, optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl C 1 -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC 1 -4alkyl, or R24 and
R25 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur; Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C i- i o alkyl, C2-10 alkenyl, C i - io alkoxy, halosubstituted C i-io alkoxy, (CRgRg)q S(O)tR4, hydroxy, hydroxyC 1 -4alkyl, aryl, aryl C i-4 alkyl, aryloxy, arylC i-4 alkyloxy, heteroaryl, heteroaryl C i -4 alkyl, heteroaryl C i-4 alkyloxy, heterocyclic, heterocyclicC 1 -4alkyl, aryl C2- 10 alkenyl, heteroarylC2-10 alkenyl, heterocyclicC2-10alkenyl, (CRgR8)qNR4R5,
C2-10alkenylC(O)NR4R5, (CRgR8)qC(0)NR4R5, (CR8R8)qC(O)NR4Rl0, S(O)3R8, (CR8R8)qC(O)Ri 1, C2-10 alkenylC(O)Rι 1, C2-10alkenylC(O)ORi 1, (CR8Rg)qC(O)ORi2, (CRgR )q OC(O) Rn , (CR8Rg)qNR4C(O)Rι 1, (CRgRg)qC(NR4)NR4R5, (CR8R8)q NR4C(N 5)R! (CR8R8)qNHS(O)2Rι g, or (CRgRg)qS(O)2NR4R5; or two Y moieties together may form O-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted,
the E containing ring is optionally selected from
the asteπx * denoting point of attachment of the ring, or a pharmaceutically acceptable salt thereof
DETAILEP PESCRIPTION OF THE INVENTION The compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 α and β receptors Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section In compounds of Formula (I), suitably Ri is independently selected from hydrogen, halogen; nitro, cyano, halosubstituted Ci-io alkyl, such as CF3, Ci-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl, C2-10 alkenyl, Ci-io alkoxy, such as methoxy, or ethoxy, halosubstituted C 1.10 alkoxy, such as trifluoromethoxy, azide, (CR8R8)q S(O)tR4, wherein t is 0, 1 or 2, hydroxy, hydroxy C ι_4alkyl, such as methanol or ethanol, aryl, such as phenyl or naphthyl, aryl C1.4 alkyl, such as benzyl, aryloxy, such as phenoxy, aryl C i-4 alkyloxy, such as benzyloxy, heteroaryl, heteroarylalkyl, heteroaryl C1.4 alkyloxy, aryl C2-10 alkenyl , heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CRgR8)qNR4R5, C2-10 alkenyl C(O)NR4R5, (CR8R8)q C(0)NR4R5, (CR8R8)q C(O)NR4RlO, S(0)3H, S(O)3R8, (CR8R8)q C(0)R 1 1, C2-IO alkenyl C(O)R 1 1 , C2- 10 alkenyl C(O)OR 1 1 , C(O)R 1 1 , (CR8R8)q C(O)ORi2, (CR8R8)q OC(O)Rι l , (CRgRg)qNR4C(O)Rl 1 , (CRgRg)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)R1 l f (CRgR8)q NHS(O)2Rι7, or (CRgRg)q S(O)2NR4R5, or two Ri moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring All of the aryl, heteroaryl, and heterocyclic containing moieties above may be optionally substituted as defined herein below Suitably m is an integer having a value of 1 to 3
Suitably, s is an integer having a value of 1 to 3 Suitably, q is 0, or an integer having a value of 1 to 10 When Ri forms a dioxybridge, s is preferably 1 When Ri forms an additional saturated or unsaturated ring, it is preferably 6 membered unsaturated ring resulting in a naphthalene ring system These rings may be optionally substituted independently, 1 to 3 times, by other Ri moieties as defined above
Suitably, R4 and R5 are independently hydrogen, optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Cι_4alkyl, heterocyclic, heterocyclicC 1.4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S
Suitably, R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur
Suitably, Rg is independently hydrogen or C 1.4 alkyl
Suitably, Rio is Ci-io alkyl C(O)2R8, such as CH2C(0)2H or CH2C(O)2CH3
Suitably, Rj 1 is hydrogen, C 1.4 alkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroaryl C 1 _4aikyl, heterocyclic, or heterocyclic C 1 _4alkyl
Suitably, R12 is hydrogen, C 1-10 alkyl, optionally substituted aryl or optionally substituted arylalkyl Suitably, R13 and R14 are independently hydrogen, an optionally substituted Ci-4 alkyl which may be straight or branched as defined herein, or one of R13 and Rl4 are an optionally substituted aryl, v is 0, or an integer having a value of 1 to 4
When Rj3 or Rj 4 are an optionally substituted alkyl, the alkyl moiety may be substituted one to three times independently by halogen, halosubstituted Ci-4 alkyl such as trifluoromethyl, hydroxy, hydroxy C 1 -4alkyl, C 1.4 alkoxy, such as methoxy, or ethoxy, halosubstituted C i-io alkoxy, S(O)tR4, aryl, NR4R5, NHC(O)R4, C(O)NR4R5, or C(O)ORg
Suitably, R17 is Ci-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclic, or heterocyclicC ι_4alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted
Suitably, Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C i-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR8R8)q S(O)tR4, hydroxy, hydroxyC ι_4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, arylCi-4 alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl Ci-4 alkyloxy, heterocyclic, heterocyclic C i-4alkyl, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CR8Rg)q NR4R5, C2-10 alkenyl C(O)NR4R5, (CRgR8)q C(O)NR4R5, (CRgR8)qC(O)NR4RlO, S(O)3Rg,
(CR8R8)q C(O)Rn , C2-10 alkenyl C(0)Rn, C2-10 alkenyl C(O)ORι 1 , (CRgRg)q C(0)ORi2, (CRgRg)q OC(O) Rl l, (CR8R8)q NR4C(O)Rι 1 , (CR8R8)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)Rι h (CRgRg)qNHS(O)2Rι8, (CR8R8)q S(O)2NR4R5 or two Y moieties together may form 0-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring The aryl, heteroaryl and heterocyclic containing moieties noted above may all be optionally substituted as defined herein Suitably, n is an integer having a value of 1 to 3
When Y forms a dioxybridge, s is preferably 1 When Y forms an additional saturated or unsaturated ring, it is preferably 6 membered unsaturated ring resulting in a naphthalene ring system These rings may be optionally substituted 1 to 3 times by other Y moieties as defined above
Suitably, Rj is NRgR7, alkyl, aryl C 1.4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C 1 _4alkyl, heteroarylC2_4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted Y is preferably a halogen, C ι .4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or aryl Ci-4 alkoxy, methylenedioxy, NR4R5, thio C 1 -4alkyl, thioaryl, halosubstituted C 1 - 10 alkoxy, optionally substituted C 1 -4 alkyl, or hydroxy Ci-4 alkyl Y is more preferably a mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl More preferably these groups are mono or disubstituted in the 2'- position or 2'-, 3 '-position when Z is W and W is a phenyl ring (such as when no E group is present)
While Y may be substituted in any of the 5 ring positions when W is a phenyl moiety, Y is preferably mono-substituted in the 2'-position or 3'- position, with the 4'- preferably being unsubstituted If the phenyl ring is disubstituted, the substituents are preferably in the 2' or 3' position of a monocyclic ring While both Rj and Y can both be hydrogen, it is preferred that at least one of the rings be substituted, preferably both rings are substituted
A is suitably CR20R21
Suitably R20 and R21 are independently hydrogen, halogen, cyano, halosubstituted Cl-io alkyl, Cj-io alkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroarylC 1 _4alkyl, heterocyclic, heterocyclic C i-4alkyl, (CRgRg)q OR4, (CRgRg)q C(0)Ri 1, (CRgR8)q C(0)ORi2, (CR8R8)q OC(O) Rl 1, (CR8R8)q NR4R5, (CR8R8)q NR4C(O)Rι 1, or (CRgR8)q C(O)NR4RJ O, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted, provided that both R20 and R21 are not hydrogen.
Suitably R15 and R\ are independently hydrogen, or an optionally substituted C1-4 alkyl as defined above for R13 and R14
In compounds of Formula (I), suitably Z is W, optionally substituted heteroaryl, optionally substituted C5_8 cycloalkyl, optionally substituted C ι_ } Q alkyl optionally substituted C2-10 alkenyl, or an optionally substituted C2.10 alkynyl Suitably, W is , or
Suitably, the E containing ring is optionally selected from
The E containing ring, denoted by its point of attachment through the asterix
(*), may optionally be present If not present the ring is a phenyl moiety which is substituted by the Y terms as shown The E ring may be substituted by a (Y)n moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated ring(s)
When Z is an optionally substituted C5_8 cycloalkyl ring, the ring may be substituted by (Y)n as defined above
When Z is an optionally substituted C ι_jo alkyl an optionally substituted C2_ιo alkenyl, or an optionally substituted C2-10 alkynyl, these moieties may be optionally substituted one or more times independently by halogen, nitro, cyano, halosubstituted Ci-io alkyl, such as trifluoromethyl, C i-io alkoxy, halosubstituted Ci-io alkoxy, S(O)tR4, hydroxy, hydroxy C i-4alkyl, aryloxy, arylC ι.4 alkyloxy; heteroaryloxy, heteroaryl C 1.4 alkyloxy, heterocyclic, heterocyclic C 1 -4alkyl, heterocyclicoxy, heterocyclic C 1.4 alkyloxy, NR4R5, C(O)NR4Rs, C(O)NR4Rιo, S(O)3R8, C(O)R 1 1 , C(0)OR 12, OC(O) R 1 1 , or NR4C(O)R 1 1
When Z is an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl these moieties may also, in addition to those moieties noted above, may also be optionally substituted with aryl, aryl C 1.4 alkyl, heteroaryl, and heteroaryl C ] -4 alkyl In compounds of Formula (I), when Z is a heteroaryl (HET) ring, it is suitably a heteroaryl πng or πng system If the HET moiety is a multi ring system, the πng containing the heteroatom does not need to be directly attached to the urea moiety All the rings in this ring system may be optionally substituted as defined herein Preferably the HET moiety is a pyπdyl, which may be 2-, 3- or 4-pyπdyl If the ring is a multi system πng it is preferably benzimidazole, dibenzothiophene, or an indole πng Other heterocyclic πngs of interest include, but are not limited to thiophene, furan, pyπmidine, pyrrole, pyrazole, quinohne, isoquinoline, quinazolinyl, pyπdine, oxazole, thiazole, thiadiazole, tπazole, lmidazole, or benzimidazole
In compounds of Formula (I), the HET ring may be optionally substituted independently one to three times by Y n) as defined above
Suitably, Rj is NR R7, alkyl, arvlC \ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C ι_4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the alkyl, aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted as defined herein
In compounds of Formula (I), X is suitably cyano, ORi j, C(O)NR24R25, R23, C(0)Rj !, C(0)ORι h or S(O)2R22
Suitably, R22 is Ci-4 alkyl, NR15R16, OR] ], optionally substituted aryl, optionally substituted aryl C 1 -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl
Suitably, R23 is optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl
Suitably, R24 and R25 are independently hydrogen, optionally substituted C i- 4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC 1 -4alkyl, or R24 and
R25 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur.
As used herein, "optionally substituted" unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted Ci-ioalkyl; Ci-io alkoxy, such as methoxy or ethoxy; S(0)m' Ci-io alkyl, wherein m1 is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR4R5 group; NHC(O)R4; C(O)N 4R5; C(O)OH; S(O)2NR4R5; NHS(O)2Rl9, Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted Cl-10 alkyl, such CF3; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, optionally substituted heterocylic, optionally substituted heterocylicalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl , heteroaryl, or heterocyclic moieties may be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; C l-10 alkoxy;
S(0)m'Ci-io alkyl; amino, mono & di-substituted amino, such as in the NR4R5 group; Ci-io alkyl, or halosubstituted Ci-io alkyl, such as CF3.
Rl9 is suitably Ci-4 alkyl, aryl, aryl Ci-4alkyl, heteroaryl, heteroarylC 1 _4alkyl, heterocyclic, or heterocyclicC 1 -4alkyl.
It is recognized that the guanidine functionality may have a number of different tautomers, such as RN -C(=NX) -NZ; RN =C(N-X) -NZ; R-N -C(-NX) =NZ, all of which are within the scope of this invention; and wherein the Z term contains the W and E containing ring system as defined for compounds of Formula (I).
Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. The following terms, as used herein, refer to:
• "halo" - all halogens, that is chloro, fluoro, bromo and iodo. • "C ι_ιoalkyl" or "alkyl" - both straight and branched chain radicals of 1 to
10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, //-propyl, /so-propyl, //-butyl, sec-butyl, /sø-butyl, tert-butyl, //-pentyl and the like.
• The term "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
• The term "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl and the like.
• "aryl" - phenyl and naphthyl;
• "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
• "heterocyclic" (on its own or in any combination, such as "heterocyclicalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
• The term "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
• "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)2 moiety.
• The term "wherein two R ] moieties (or two Y moieties) may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of a ring system, such as a napthylene ring system or a phenyl moiety having attached a 6 membered partially unsaturated ring attached, such as a C cycloalkenyl, i.e. hexene, or a C5 cycloalkenyl moiety, cyclopentene.
Exemplified compounds of Formula (I) include: N-[4-Chloro-(l,3)-dihydro-2,2-dioxo-2, l-benzisothiazo-7-yl]-N'-[2- bromophenyl] -N"-cyanoguanidine
Methods of Preparation
The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided for in these Schemes is applicable for the producing of Formula (I) having a variety of different Z, R\, and E' groups which are reacted, employing optional substituents which are suitably protected to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. Once the substituted guanidine nucleus has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art. While the schemes are shown with various compounds of Formula (I) this is merely for illustration purposes only and not a limitation on the extent of synthesis available using these methods.
Scheme 1
a) KSC(=0)CH3 b) Cl2, AcOH/H20 c) NH4OH d) K2C03, Cu
If the desired heterocyclic compound (5, Scheme 1) is not commercially available, the commercially available 2,6-dichlorobenzylbromide can be treated with potassium thioacetate to form the thioacetate, followed by oxidation using chlorine gas in ACOH/H2O to form the sulfonyl chloride (3, Scheme 1). The sulfonyl chloride can be converted to the corresponding sulfonamide (4, Scheme 1) by using NH4OH followed by acidification. The cyclic sulfonamide (5, Scheme 1) can be cyclized under basic conditions such as potassium carbonate using copper as catalyst followed by acidification.
Scheme 2
R20=H, H R21 = Me, propyl a) NaH, allyl bromide b) Na[(CH3)3Si]2N, Mel or CH3(CH2)2I c) NaN03, H2S04/H20 or NH4N03, TFAA d) SnCI2
Cyclic sulfonamide (ό^Scheme 2) can be prepared by protection of the nitrogen using allyl bromide, followed by alkylation of the methylene with alkyl halide in the presence of a strong base such as sodium hexamethyldisilazane. The nitro compound (8, Scheme 2) can be prepared from _7, (Scheme 2) using standard nitration conditions (using NaNO3 or NH4NO3), then reduced to the corresponding aniline (9, Scheme 2) with stannous chloride using standard conditions in a polar solvent such as methanol, ethanol, DMF, or ethyl acetate. Scheme 3
R20=Me, H R21 = Me, F a) NaN03, H2S04/H20 b) NaH, allyl bromide c) NaH, Mel or Li[(CH3)3Si]N, (PhS02)2NF d)SnCI2, EtOH
An alternative method for forming the aniline compound (9, Scheme 2) is shown in Scheme 3. The unprotected nitro compoundQO, Scheme 3)can be prepared from (5, Scheme 1), under standard nitration conditions (using HN03 or NaNO3) at
23 °C. The aniline compound (9, Scheme 2) can be prepared by protection of the nitrogen of J_0 with allyl bromide, followed by alkylation of methylene with alkyl halide and reduction with SnCb in EtOH.
Scheme 4
a) 2-BrPhNCS, DMF or b) thiophosgene, NaHC03 c) 2-bromoaniline
Ortho substituted heterocyclic phenyl thioureas Q2, Scheme 4) may be prepared by standard conditions involving the condensation of the commercially available optionally substituted aryl isothiocyanate with the corresponding aniline 9_in an aprotic solvent (such as DMF). the aniline I0_may be reacted in a 2 step process to form the thioureas 12, by treatment of aniline 10 with thiophosgene to form the isothiocyanate (ϋ, Scheme 4) and then reacting this with a commercially available optionally substituted aniline.
Scheme 5
a) MeS02CI, Et3N b) NH2CN for(X=CN), Hunig's base c) NaBH4, Pd(Ph3P)4
The carbodiimide (14, Scheme 5) is prepared from the thiourea Q2, Scheme
4) by reaction with methanesulfonyl chloride and a tertiary amine base like triethyl amine as described by Fell and Coppola (Fell ,J. B., Coppola, J. B., Syn Communications 25, 43, 1995). The carbodiimide may also be prepared by treatment with phosgene and a tertiary amine or by reaction the thiourea J_2 with triphenylphosphine, carbon tetrachloride and triethylamine.
The title compound may be synthesized by reaction of the protected carbodiimide (14, Scheme 5) with the anion NH-X (formed from reaction of NH2X with a base such as NaH) or the neutral species NH2X (X=CN) and a tertiary amine base such as Hunig's base or triethylamine under conditions where the nucleophile is present in large excess and the reaction time is kept as short as possible by carefully monitoring the reaction for completion followed by deprotection of the allyl with a palladium catalyst in the presence of a nucleophile such as NaBH4.
Alternatively, suitable substituted guanidines may be prepared as described in PCT application PCT US97/13863, PCT application PCT US97/13864; and PCT application PCT US97/ 13858 whose disclosures are incorporated herein by reference in their entirety.
Another aspect of the present invention is the chemical intermediate of Formula (II), as represented by the structure: o
\\
A -s °
N-Ra
(Rι)m-
" "N NH2
(II)
wherein A, Rj, m are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group. Another aspect of the present invention is the chemical intermediate of
Formula (IV), as represented by the structure:
° (IV)
wherein A, Rj, m are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group.
N-Ra (Rι) -^- ,J
N ' N
^N — (CR13R14)v-Z (m) wherein A, Rj, m, v, Z, Rj3 and R14 are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group.
Another aspect of the present invention is a process of making a compound of Formula (1) which process comprises reacting a carbodiimide of the formula O o
A-S
N-Ra
(R1)m —
N N
N — (CR13R14)v-Z (m) wherein A, Rj, m, v, Z, Rj 3 and R]4 are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group,with NH-X or NH2X, and a tertiary amine to yield a compound of Formula (I), and thereafter if necessary, deprotecting to yield a compound of Formula (I), wherein X is cyano.
SYNTHETIC EXAMPLES
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents are highest available purity and all reactions run under anhydrous conditions in an argon atmosphere unless otherwise indicated.
In the Examples, all temperatures are in degrees Centigrade (°C). Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated. ^H-NMR (hereinafter "NMR") spectra were recorded at 400 MHz using a Bruker or Am 400 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal. Sat. indicates a saturated solution, eq indicates the proportion of a molar equivalent of reagent relative to the principal reactant .
Example 1 Preparation of N-|"4-chloro -l,3-dihvdro-2.2-dioxo -1.2-benzisothiazo)-7-yl]-N'-[2- bromophenyl]-N"-cyanoeuanidine a) Preparation of 2,6-Dichlorobenzylthioacetate To a solution of 2,6-dichlorobenzylbromide (60 grams (hereinafter "g"), 248 millimole (hereinafter "mmol")) in DMF (200 milliliter (hereinafter "ml")), potassium thioacetate (31.3 g, 276 mmol) was added. The reaction mixture was stirred at room temperature for two hr. Then it was partitioned between ethyl acetate and water. The combined organic phase was dried and concentrated to give a yellow oil (58.71 g, 99%). EI-MS m/z 235, 237 (M+H) \ 257,259 (M+Na) * b) Preparation of 2,6-Dichlorobenzylsulfonylchloride
The 2,6-dichlorobenzylthioacetate (29 19 g, 124 mmol) and sodium acetate (68 g) were dissolved in a mixture of glacial acetic acid (646 ml) and water (141 ml)
Chlorine gas was passed into the solution for 15 minutes (hereinafter "min") The mixture was evaporated and the residue was extracted with t-butyl-O-methyl ether
The combined organic phase was dried and concentrated to give the desired product as a white solid (24 1 g, 75 %) NMR(400 MHz,CDCl3) 7 45 (d, J=7 7Hz, 2H),
7 36 (t, J=8Hz, 1H), 5 44 (s, 1H)
c) Preparation of 2,6-Dichlorobenzylsulfonamide
The 2,6-dichlorobenzylsulfonylchloride (23 9 g, 92 3 mmol) in cone ammonium hydroxide (200 ml) was stirred at room temperature overnight On acidification at - 10° with cooled concentrated hydrochloric acid a precipitate separated and was filtered to give desired product as white crystalline plates (14 38 g, 65 %) EI-MS m/z 240, 242 (M+H) ÷
d) Preparation of 4-Chloro-l,3-dihydro-2,2-dioxo-l,2-benzisothiazole
The 2,6-dichlorobenzylsulfonamide (5 g, 20 92 mmol) was added to potassium carbonate (2 89 g, 20 92 mmol), copper powder (376 mg) and N,N-dimethylaniline
(30 ml) in a round bottom flask. The reaction mixture was stirred at 170°C for 4 hr then was cooled to room temperature and partitioned between t-butyl-O-methyl ether and 1 N aqueous HC1 and further extracted (x3) with t-butyl-O-methyl ether The combined organic phases were washed with 1 N HC1 (3), water (x3) and brine, then dried (MgS04) and concentrated to give the desired product (4 2 g, 98%) NMR(400
MHz,CDCl3) 7 24 (t, J=8Hz, 1H), 7 06 (d, J=8Hz, 1H), 6 96 (s, 1H), 6 79 (d, J=8Hz, 1H), 4 42 (s, 2H), MS(ES") m/e 202, 204 [M-H]"
e) Preparation of l-Allyl-4-chloro-2,2-dioxo-l,2-benzisothiazoline The 4-chloro-l,3-dihydro-2,2-dioxo-l,2-benzisothiazole was azeotroped from toluene to remove water prior to its use A solution of dry 4-chloro-l,3-dihydro- 2,2-dioxo-2,l-benzisothiazole (5 2 g, 25 53 mmol) in DMF (15 ml) was added dropwise to a slurry of sodium hydride ( 60%, 1 072 g ,26 8 mmol) and after 15 min , allyl bromide (2 43 ml, 28 08 mmol) was added The reaction mixture was stirred at room temperature for 16 hours Then it was partitioned between ethyl acetate and water The combined organic phase was dried and concentrated to give desired product (6 04 g, 97 %) NMR(400 MHz.CDCl3) 7 21 (t, J=8 17Hz, IH), 6 97 (d, J=8 2Hz IH), 6 62 (d, J=8 17Hz, IH), 5 93-5 86 (m, IH), 5 38 (d, J=17 1Hz IH), 5 30 (d, J=10 3Hz, IH), 4 36 (s, 2H), 4 19 (d, J=5 4H)
f) Preparation of l-Allyl-4-chloro-2,2-dioxo-7-nitro-l,2-benzisothiazohne
1 -Allyl-4-chloro -2,2-dioxo-l,2-benzιsothιazoline (4 24 g, 17 4 mmol) was dissolved in chloroform (25 ml) followed by the addition of ammonium nitrate ( 1 5 g, 18 7 mmol) and trifluoroacetic anhydride ( 15 ml) The mixture is allowed to stir at room temperature under Ar After 72 hours, the reaction mixture was concentrated under reduced pressure and the residue was partitioned between t-butyl-O-methyl ether and 5% NaHC03 then further extracted with ether The combined organic layers were dried over MgS0 and filtered The solvent was evaporated and chromatography of the resulting solid on silica gel (15% ethyl acetate/hexane) gave the desired product with slight impurities Recrystallization from ethanol of the columned material gave pure product (998 mg, 19 9 %) NMR(400 MHz,CDCl3) 7 91 (d, J=9Hz, IH), 7 19
(d, J=9 1Hz, IH), 5 65-5 55 (m, IH), 5 24 (dd, J=17 2Hz, J=10Hz, 2H), 4 43 (m, 4H)
g) Preparation of l-Allyl-7-amino-2,2-dioxo-4-chloro-l,2-benzisothiazoline To the solution of l-allyl-4-chloro-2,2-dioxo-7-nitro-l ,2-benzisothiazoline ( 1 184 g,
4 1 mmol) in ethanol (120 ml), tin (II) chloride (4 g, 17 7 mmol) was added The reaction mixture was stirred at room temperature for 18 hrs Then EtOH was removed under reduced pressure, the NaHCO3 (aqueous) was added to the reaction mixture The tin salts were removed by filtration The filtrate was extracted with ethyl acetate (3x) The combined organic layers were washed with 5% NaHC03, water and then brine, dried over MgSO4, filtered and concentrated under reduced pressure to give (1.2 g) This was chromatographed (silica gel) to afford the desired product as a yellow crystalline solid (720 mg, 69%) EST-MS m/z 259, 261 (M+H) τ
h) Preparation of l-Allyl-4-chloro-2,2-dioxo-7-isothiocyanato-l,2-benzιsothiazoline
To a stirred mixture of l-allyl-7-amino-4-chloro-2,2-dioxo-l,2-benzisothiazoline
(258 mg, 1 mmol), chloroform (50 mL), sodium bicarbonate ( 1 25 g 14 8 mmol) and water (25 mL) was added thiophosgene (266 uL, 3 3 mmol) After stirring 72 hr at room temperature, tic indicated that starting material was still present, thiophosgene ( 133 uL, 1 65 mmol) was added After stirring overnight, the mixture was extracted (x3) with chloroform, dried (MgSθ4) and evaporated under reduced pressure to afford the desired product in quantitative yield. NMR(400 MHz,CDCl3) 7.25 (d, 1H),7.04 (d, IH), 5.92 (m, IH), 5.42 (d, IH) 5.31 (d, IH), 4.52 (d, 2H) 4.34 (s, 2H);
i) Preparation of N-[(l-Allyl-4-chloro-2,2-dioxo-l,2-benzisothiazolin)-7-yl]-N' (2- bromophenyl)thiourea
To a solution of 2-bromoaniline (172 mg, 1 mmol) in DMF (5.0 mL), l-allyl-2,2- dioxo-4-chloro-7-isothiocyanato -2, 1-benzisothiazoline (300 mg, 1 mmol) was added. The reaction mixture was stirred at rt for 16 hrs. The reaction mixture was partitioned between ethyl acetate and 0.5 M sodium dihydrogen phosphate and further extracted with ethyl acetate. Drying (MgSO4) and evaporation under reduced pressure gave a yellow oil which was recrystallized from chloroform to give the desired product as a white solid.(338 mg, 72%). MS(ES+) m/e 472, 474, 476 [M+H]+; MS(ES-) m/e 470, 472, 474 [M-H]'.
j) N-[(l-Allyl-4-chloro-2,2-dioxo-l,2-benzisothiazolin)-7-yl]-N'-(2-bromophenyl)- carbodiimide
To a stirred solution of N-[(l-allyl-2,2-dioxo-4-chloro-l,2-benzisothiazolin)- 7-y_]-N'-[2-bromophenyl] thiourea (335 mg, 0.71 mmol) and triethylamine (0.3 ml, 2.1 mmol) in methylene chloride was added dropwise at 0° methanesulfonyl chloride (115 uL, 1.48 mmol) under Ar. The reaction was stirred for 15 minutes at 0° and tic showed no starting material present. The reaction mixture was chromatographed on silica gel eluting with methylene chloride to afford the title compound as a tan solid (338 mg, > 100%). This was used in the next reaction without further purification. IR(KBr) 2146, 2108 cm"1 ;
k) N-[( 1 -Allyl-4-chloro-2,2-dioxo- 1 ,2-benzisothiazolin)-7-yl]-N'-(2-bromophenyl)- N"-cyanoguanidine.
To a stirred mixture of cyanamide (330 mg, 8 85 mmol) and Huinig's base (0 66 ml) in acetonitrile was added a solution of N-[(l-allyl-4-chloro-2,2-dioxo-2, 1 - benzisothiazolin)-7-yl]-N'-(2-bromophenyl)-carbodiimide (330 mg, 0 7 mmol) in acetonitrile (25 mL) dropwise The reaction was stirred at room temperature for 15 min , then the solvent was removed under reduced pressure and the residue hydrolyzed with 0 5 M sodium dihydrogen phosphate Ethyl acetate extraction's of the aqueous mixture were washed with 0 5 M sodium dihydrogen phosphate and brine After drying (MgS04) filtration and evaporation under reduced pressure afforded a crude tan solid (500 mg) This was chromatographed on silica gel (2% methanol/chloroform) to give the title compound as a cream colored solid (280 mg, 82%) MS(ES-) m/e 478, 480, 482 [M-H]"
l) N-[(4-Chloro-l,3-dihydro-2,2-dioxo-l,2-benzisothiazo)-7-yl]-N'-(2-bromophenyl)- N"-cyanoguanidine To a mixture of N-[(l-allyl-4-chloro-2,2-dioxo-l,2-benzιsothiazolin)-7-yl]-N'-
(2-bromophenyl)-N"-cyanoguanidine (80 mg, 0 166 mmol) and sodium borohydride (20 mg, 0 21 mmol) in THF (8 mL) was added at room temperature tetrakistriphenylphosphine palladium[0] (8 mg) The reaction was stirred at room temperature for 2 hr The mixture was partitioned between ethyl acetate and 0 5 M sodium dihydrogen phosphate After drying over MgSO4 filtration and evaporation under reduced pressure afforded a crude tan solid (100 mg) Column chromatography on silica gel eluting with 5% methanol/chloroform gave a pale yellow solid (10 mg) which was recrystallized from ethyl acetate/hexane to give the desired product (5 mg, 7%) IH NMR(400 MHz,CD CN) 7 70 (d, J=8Hz, 1H),7 52 (d, J=8 Hz, IH), 7 43 (t, IH), 7 26- 7 21 (m, 2H) 7 05 (d, IH), 4 47 (d, 2H), IR(KBr) 2183, 1603, 1580, 1548 cm"1 , MS(ES") m/e 438,440, 442 [M-H]", MS(ES+) m/e 440,442,444 [M+H]+, mp 135-140°
METHOD OF TREATMENT The compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines which bind to the IL-8 α or β receptor, also referred to as the type I or type II receptor Accordingly, the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof In particular, the chemokines are IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78
The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GROα, GROβ, GROγ, NAP-2 or ENA- 78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state Abnormal levels of IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 for instance in the context of the present invention, constitute (i) levels of free IL-8 greater than or equal to 1 picogram per mL, (ii) any cell associated IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 above normal physiological levels, or (iii) the presence IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 above basal levels in cells or tissues in which IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 respectively, is produced There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs host reaction, Alzheimer's disease, allograft rejections, malaria, restinosis, angiogenesis or undesired hematopoietic stem cells release, rhinovirus infections, periodontal disease, and various bone resorption indications, such as osteoporosis or osteoarthritis
The association of interleukin-8 and rhinovirus may be found in articles such as Turner, et al , Clin Infect. Dis (1998), 26(4), 840-846, Sanders, et al , J Virol (1998), 72(2), 934-942, Sethi, et al , Clin Exp Immunol (1997), 1 10(3), 362-369, Zhu, et al , Am J Physiol (1997), 273(4, Pt 1), L814-L824, Terajima, et al , Am J Physiol (1997), 273(4, Pt 1), L749-L759, Grunberg, et al , Clin Exp Allergy (1997), 27(1), 36-45, and Johnston, et al . J Infect Dis (1997), 175(2), 323-329 The association of interleukin-8 and osteoporosis may be found in articles such as Streckfus et al , J Gerontol , Ser A (1997), 52A(6), M343-M351 , Hermann, T WO 95/31722, and Chaudhary, et al , Endocrinology (Baltimore) (1992), 130(5), 2528-34 These diseases are primarily characterized by massive neutrophil infiltration, T-cell infiltration, or neovascular growth, and are associated with DL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells In contrast to other inflammatory cytokines (IL-8, GROα, GROβ, GROγ, or NAP-2) has the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation The α-chemokines but particularly, GROα, GROβ, GROγ, or NAP-2, working through the IL-8 type I or II receptor can promote the neovascularization of tumors by promoting the directional growth of endothelial cells Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration
Recent evidence also implicates the role of chemokines in the treatment of HIV infections, Littleman et al , Nature 381 , pp 661 ( 1996) and Koup et al , Nature 381, pp 667 (1996)
Present evidence also indicates the use of IL-8 inhibitors in the treatment of atherosclerosis The first reference, Boisvert et al , J Clin Invest, 1998, 101 353-363 shows, through bone marrow transplantation, that the absence of IL-8 receptors on stem cells (and, therefore, on monocytes/macrophages) leads to a reduction in the development of atherosclerotic plaques in LDL receptor deficient mice Additional supporting references are Apostolopoulos, et al , Arterioscler Thromb Vase Biol 1996, 16 1007-1012, Liu, et al , Arterioscler Thromb Vase Biol, 1997, 17 317-323, Rus, et al , Atherosclerosis 1996, 127 263-271 , Wang et al , J Biol Chem 1996, 271 8837-8842, Yue, et al , Eur J Pharmacol 1993, 240 81 -84, Koch, et al , Am J Pathol, 1993, 142 1423-143 1 , Lee, et al , Immunol Lett, 1996, 53, 109-1 13 , and Terkeltaub et al , Arterioscler Thromb, 1994, 14 47-53
The present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I) CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region Also included within this definition is ischemic stroke, particularly to the brain area
Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel The role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
TNF-α is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al., Stoke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.
Models of closed head injuries and treatment with mixed 5-LO/CO agents is discussed in Shohami et al., J. of Vaisc & Clinical Physiology and Pharmacology, Vol. 3, No. 2, pp. 99-107 (1992) whose disclosure is incorporated herein by reference. Treatment which reduced edema formation was found to improve functional outcome in those animals treated.
The compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation. The discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein. The compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.
As used herein, the term "IL-8 mediated disease or disease state" refers to any and all disease states in which IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 plays a role, either by production of IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 themselves, or by IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
As used herein, the term "chemokine mediated disease or disease state" refers to any and all disease states in which a chemokine which binds to an IL-8 α or β receptor plays a role, such as but not limited IL-8, GROα, GROβ, GROγ, NAP-2 or ENA-78. This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8. As used herein the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response A cytokine includes, but is not limited to, monokines and lymphokines. regardless of which cells produce them For instance, a monokine is generally referred to as being produced and secreted bv a mononuclear cell, such as a macrophage and/or monocyte Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B-lymphocytes Lymphokines are generally referred to as being produced by lymphocyte cells Examples of cytokines include, but are not limited to, Interleukin- 1 (IL-1), Interleukιn-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNF-β)
As used herein, the term "chemokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine" above A chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells Examples of chemokines include, but are not limited to, IL-8, GRO-α, GRO-β, GRO-γ, NAP-2, ENA-78, IP- 10, MlP-lα, MlP-β, PF4, and MCP 1, 2, and 3
In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent
Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical earners according to conventional procedures The compounds of Formula (I) may also be administered in conventional dosages m combination with a known, second therapeutically active compound
These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof
The pharmaceutical carrier employed may be, for example, either a solid or liquid Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax
A wide variety of pharmaceutical forms can be employed Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg to about lg When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension. Compounds of Formula (I) may be administered topically, that is by non- systemic administration This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0 001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0 1% to 1% w/w of the Formulation
Lotions according to the present invention include those suitable for application to the skin or eye An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil, wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C for half an hour Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0 002%), benzalkonium chloride (0 01%) and chlorhexidine acetate (0 01%) Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration The subcutaneous and intramuscular forms of parenteral administration are generally preferred Appropriate dosage forms for such administration may be prepared by conventional techniques Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation
1 - administration Appropnate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques
For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 0 01 to about 80 mg/kg of total body weight The daily parenteral dosage regimen about 0 001 to about 80 mg/kg of total body weight The daily topical dosage regimen will preferably be from 0 1 mg to 150 mg, administered one to four, preferably two or three times daily The daily inhalation dosage regimen will preferably be from about 0 01 mg/kg to about 1 mg/kg per day It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques It will also be appreciated by one of skill in the art that the optimal course of treatment, i e , the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests
The invention will now be described by reference to the following biological examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention
BIOLOGICAL EXAMPLES The EL-8, and GRO-α chemokine inhibitory effects of compounds of the present invention are determined by the following /// vitro assay
Receptor Binding Assays:
[I2 iL_8 (human recombinant) is obtained from Amersham Corp , Arlington Heights, IL, with specific activity 2000 Ci/mmol GRO-α is obtained from NEN- New England Nuclear All other chemicals are of analytical grade High levels of recombinant human IL-8 type α and β receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, et al.. Science, 1991, 253, 1278) The Chinese hamster ovary membranes were homogenized according to a previously described protocol (Haour, et al , J Biol Chem , 249 pp 2195-2205 (1974)) Except that the homogenization buffer is changed to l OmM Tris-HCL, lmM MgS04, 0.5mM EDTA (ethylene-diaminetetra-acetic acid), ImMPMSF (α- toluenesulphonyl fluoride), 0 5 mg L Leupeptin, pH 7 5 Membrane protein concentration is determined using Pierce Co micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format Each reaction mixture contains ^ j IL_8 (o 25 nM) or 125] Gro-α and 0 5 μg/mL of IL-8Rα or 1 0 μg/mL of IL-8Rβ membranes in 20 mM Bis-Trispropane and 0 4 mM Tris HC1 buffers, pH 8 0, containing 1 2 mM MgSO4, 0 1 mM EDTA 25 mM NaCl and 0 03% CHAPS In addition, drug or compound of interest is added which has been pre-dissolved in DMSO so as to reach a final concentration of between 0 OlnM and 100 uM The assay is initiated by addition of ^^l-JL-S After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethylenimine/0 5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl, 1 mM MgSO4, 0 5 mM EDTA 0 03 % CHAPS, pH 7 4 The filter is then dried and counted on the Betaplate liquid scintillation counter The recombinant IL-8 Rα, or Type 1, receptor is also referred to herein as the non- permissive receptor and the recombinant IL-8 Rβ, or Type II, receptor is referred to as the permissive receptor.
A representative compound of Formula (I), Example 1, has been found to have positive inhibitory activity of < 30 μmg in this assay
Chemotaxis Assay •
The in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol. I, Suppl 1, Unit 6.12.3 , whose disclosure is incorporated herein by reference in its entirety Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1, whose disclosure is incorporated herein by reference in its entirety The chemoattractants IL-8, GRO-α, GRO-β, GRO-γ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0 1 and 100 nM. The two chambers are separated by a 5um polycarbonate filter When compounds of this invention are tested, they are mixed with the cells (0 001 - 1000 nM) just prior to the addition of the cells to the upper chamber Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5% CO2. At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA) Cells which have chemotaxed to the chemokine are visually counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated. Each sample is tested in triplicate and each compound repeated at least four times. To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells. In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber. The difference between the positive control and the negative control represents the chemotactic activity of the cells.
Elastase Release Assay:
The compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils. Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1. PMNs 0.88 x 106 cells suspended in Ringer's Solution (NaCl 1 18, KC1 4.56, NaHC03 25, KH2PO4 1.03, Glucose 1 1.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 ul. To this plate is added the test compound (0.001 - 1000 nM) in a volume of 50 ul, Cytochalasin B in a volume of 50 ul (20ug/ml) and Ringers buffer in a volume of 50 ul. These cells are allowed to warm (37 °C, 5% CO2, 95% RH) for 5 min. before IL-8, GROα, GROβ, GROγ or NAP-2 at a final concentration of 0.01 - 1000 nM was added. The reaction is allowed to proceed for 45 min. before the 96 well plate is centrifuged (800 xg 5 min.) and 100 ul of the supernatant removed. This supernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline. Immediately, the plate is placed in a fluorescent 96 well plate reader
(Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 min. intervals according to the method of Nakajima et al J. Biol. Chem. 254 4027 (1979). The amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.
TNF-α in Traumatic Brain Injury Assay
This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- α is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- α plays an important role in both the acute and regenerative response to CNS trauma. A suitable assay may be found in WO 97/35856 or WO 97/49286 whose disclosures are incorporated herein by reference.
CNS Injury model for IL-β mRNA
This assay characterizes the regional expression of interleukin- 1 β (IL-lβ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-l β mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-lβ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury. A suitable assay may be found in WO 97/35856 or WO 97/49286 whose disclosures are incorporated herein by reference.
In vivo - athereoschlerosis assay:
In vivo models for measuring atherosclerosis in mice is based on the assay of Paigen et al with small modifications as described below. See Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68: 231-240 (1987); and Groot PHE, van Vlijmen BJM, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, Havekes LM. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vase Biol. 16: 926-933 (1996). Sectioning and staining of the aortic sinus Cross-sections of the aortic root are taken as has been described previously
(1 ,2). Briefly, the hearts are bisected just below the level of the atria and the base of the heart plus aortic root are taken for analysis. After equilibrating the tissue in OCT compound overnight the hearts are immersed in OCT compound on a cryostat chuck (Bright Instrument Company Ltd. , UK) with the aorta facing the chuck. The tissue is frozen by surrounding the chuck with dry ice. The hearts are then sectioned perpendicular to the axis of the aorta, starting within the heart and working in the direction of the aorta. Once the aortic root has been identified by the appearance of the three valve leaflets, alternate 10 mm sections are taken and mounted on gelatinised slides. Sections are air dried for 1 hour and subsequently rinsed briefly in 60% isopropyl alcohol. The sections are stained with Oil Red O, counterstained with Mayer's haematoxylin, cover slipped using glycerol gelatine and sealed with nail varnish.
Quantification of atherosclerosis in the aortic root Ten alternate sections of the aortic root are imaged using an Olympus BH-2 microscope equipped with an 4x objective and a video camera (Hitachi, HV-C10).
Twenty-four bit colour images are acquired and analysed using a PC (Datacell
Pentium P5-133, Datacell, Berks, U.K.) fitted with a framegrabbing board (Snapper,
Active Imaging Ltd, Berks, U.K.) and running Optimas software (version 5.1, Optimas Corp., WA, U.S.A.). The images are captured under identical lighting, microscope, camera and PC conditions. Quantification of the atherosclerotic lesion areas is performed by drawing around the lesions by hand using the Optimas software.
Colour thresholds are set that quantify the areas that are stained red within the lesions.
Absolute values for the cross-sectional areas of the lesions and the areas stained red are obtained by calibrating the software using an image of the grid on a haemocytometer slide.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is Claimed Is:
A compound of the formula:
(I) wherein
A is CR2oR2i;
R is NH-C(=N-X)-NH-(CR13R1 )V - Z;
X is cyano, OR! h C(0)R! h C(0)ORl S(O)2R22, ^23, r C(O)NR24R25; Z is W, optionally substituted heteroaryl, optionally substituted C5_8 cycloalkyl, optionally substituted Cj. o alkyl, optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl; n is an integer having a value of 1 to 3; m is an integer having a value of 1 or 3; q is 0, or an integer having a value of 1 to 10; s is an integer having a value of 1 to 3; t is 0, or an integer having a value of 1 or 2; v is 0, or an integer having a value of 1 to 4;
Rl is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C 1 - 10 alkyl, C2- 10 alkenyl, C 1.10 alkoxy, halosubstituted C 1 _ 10 alkoxy, (CR8R )q S(O)tR4, hydroxy, hydroxy Ci-4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, arylCi-4 alkyloxy, heteroaryl, heteroaryl Ci-4 alkyl, heterocyclic, heterocyclicC 1 -4alkyl, heteroarylC 1.4 alkyloxy, arylC2-10 alkenyl, heteroarylC2-10 alkenyl, heterocyclicC2-10 alkenyl, (CR8R )qNR4Rs, C2-10alkenylC(O)NR4R5, (CR8R8)qC(O)NR4Rs, (CR8R8)qC(O)NR4R╬╣o,
S(O)3R8, (CRgRg)q C(O)Rj 1, C2-10 alkenylC(O)R╬╣ 1, C2-10alkenylC(O)OR╬╣ ╬╣, (CR8R8)q C(0)Rn, (CR8R8)qC(O)OR╬╣2, (CR8R8)qOC(O)Rn, (CR8R8)qNR4C(O)Ri 1, (CR8R8)qC( R4)NR4R5, (CR8R8)q NR4C(NR5)R! ], (CR8R8)q NHS(O)2R╬╣7, or (CR R8)qS(O)2NR4R5, or two R\ moieties together may form O-(CH2)sO or a
5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted; R4 and R5 are independently hydrogen, optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C ╬╣_4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C╬╣_4alkyl, heterocyclic, heterocyclic C 1 -4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O N/S; R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
R8 is independently hydrogen or Ci-4 alkyl;
RlO is C 1-10 alkyl C(O)2R8;
Rl 1 is hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl
C ╬╣_4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl; Rl2 is hydrogen, Cl-10 alkyl, optionally substituted aryl or optionally substituted arylalkyl; Rl3 and R14 are independently hydrogen, optionally substituted Ci-4 alkyl, or one of R13 and R14 may be an optionally substituted aryl;
Rl 5 and Rjg are independently hydrogen, or an optionally substituted C ╬╣_4 alkyl; Rl 7 is C╬╣_4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclic, or heterocyclicC i-4alkyl; and wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted; Rj 8 is NRgR7, alkyl, arylC ╬╣.4 alkyl, arylC2-4 alkenyl, heteroaryl, heteroaryl-
C j_4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclicC 1.4 alkyl, wherein the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted; R20 and R21 are independently hydrogen, halogen, cyano, halosubstituted C 1 _ 1 oalkyl, C 1.1 oalkyl, aryl, aryl C 1.4 alkyl, heteroaryl; heteroaryl C 1.4 alkyl, heterocyclic, heterocyclic C i -4alkyl, (CR8R8)qOR4, (CR8R8)qC(O)R╬╣ 1 , (CR8R8)qC(0)ORi2, (CR8R8)qOC(O) Rl 1, (CR8R8)qNR4R5, (CR8R8)qNR4C(O)Ri 1, or (CR8R8)q C(O)NR4Rl╬╕; and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted, provided that both R20 and R21 are not hydrogen; R22 is Ci-4 alkyl, NR15R16, ORn, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl; R23 is optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC i-4alkyl; R24 and R25 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 _4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC i-4alkyl, or R24 and R25 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur;
Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR R8)q S(O)tR4, hydroxy, hydroxyC 1 -4alkyl, aryl, aryl C╬╣_4 alkyl, aryloxy, arylCi-4 alkyloxy, heteroaryl, heteroaryl Ci-4 alkyl, heteroaryl Ci-4 alkyloxy, heterocyclic, heterocyclicC ╬╣_4alkyl, aryl C2-10 alkenyl, heteroarylC2-l╬╕ alkenyl, heterocyclicC2-10alkenyl, (CR8R )qNR4R5, C2-10alkenylC(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4RlO, S(O)3R8, (CRgRg)qC(O)R╬╣ 1, C2-10 alkenylC(O)Ri 1, C2-10alkenylC(O)ORi 1, (CR8R8)qC(O)ORi2, (CR8Rg)q OC(O) Rl 1, (CR8R8)qNR4C(O)R╬╣ 1, (CR8Rg)qC(NR4)NR4R5, (CRgRg)q N 4C(NR5)R! ] ,
(CR8R8)qNHS(O)2R╬╣8, or (CR8R8)qS(O)2NR4R5; or two Y moieties together may form O-(CH2)sO or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted;
the E containing ring is optionally selected from the asterix * denoting point of attachment of the ring or a pharmaceutically acceptable salt thereof
2 The compound according to Claim 1 wherein Rl is halogen, cyano, nitro,
CF3, (CR8R8)q C(O)NR4R5, C2-10 alkenyl C(O)NR4R5, (CR R8)qC(O)NR4Rio, C2-10 alkenyl C(0)ORn, heteroaryl, heteroarylC ╬╣_4alkyl, heteroarylC2-10 alkenyl, or (CR8R8)q S(O)2NR4Rs
3 The compound according to Claim 2 wherein R\ is halogen
4. The compound according to Claim 1 wherein at least one of R20 and R21 is alkyl or halogen.
The compound according to Claim 1 wherein Z is W
6 The compound according to Claim 5 wherein Y is halogen, C╬╣_4 alkoxy, optionally substituted aryl, optionally substituted aryl C 1 -4alkoxy, methylenedioxy, NR4R5, thioC╬╣_4alkyl, thioaryl, halosubstituted Ci-io alkoxy, optionally substituted Ci-4alkyl, or hydroxy substituted Ci-4 alkyl
7 The compound according to Claim 6 wherein Y is halogen
8 The compound according to Claim 1 wherein Z is an optionally substituted heteroaryl
9 The compound according to any of Claims 1 to 8 wherein X is cyano
10 The compound according to Claim 1 which is N-[( 1 ,3)-Dihydro-2,2-dioxo-4-chloro-2, 1 -benzisothiazo-7-yl]-N'-[2- bromophenyl]-N"-cyanoguanidine
1 1. A pharmaceutical composition comprising an effective amount of a compound according to any one of Claims 1 to 10, and a pharmaceutically acceptable carrier or diluent.
12. A method of treating a chemokine mediated disease state, wherein the chemokine binds to an IL-8 ╬▒ or ╬▓ receptor in a mammal, which comprises administering to said mammal an effective amount of a compound according to Claim 1.
13. The method according to Claim 12 wherein the mammal is afflicted with a chemokine mediated disease selected from psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction,
Alzheimer's disease, allograft rejection, malaria, restinosis, angiogenesis, undesired hematopoietic stem cells release, rhinovirus infections, periodontal disease or bone resorption disease.
14. A compound of the formula:
wherein A, Rj, m are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group.
15. A process of making a compound according to Claim 1 which process comprises reacting a carbodiimide of the formula wherein A, R\, m, v, Z, Rj3 and R 14 are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting group, with NH-X or NH2X, and a tertiary amine to yield a compound of Formula (I), and thereafter if necessary, deprotecting to yield a compound of Formula (I), wherein X is cyano.
16. A compound of the formula :
— (CR13R14)v-Z (π) wherein A, R\, m, v, Z, Rj3 and R14 are as defined above for Formula (I), and Ra is hydrogen or a nitrogen protecting grou
EP99902334A 1998-01-16 1999-01-15 Il-8 receptor antagonists Withdrawn EP1039903A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7165398P 1998-01-16 1998-01-16
US71653 1998-01-16
PCT/US1999/001029 WO1999036069A1 (en) 1998-01-16 1999-01-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1039903A1 true EP1039903A1 (en) 2000-10-04
EP1039903A4 EP1039903A4 (en) 2001-12-05

Family

ID=22102724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99902334A Withdrawn EP1039903A4 (en) 1998-01-16 1999-01-15 Il-8 receptor antagonists

Country Status (5)

Country Link
EP (1) EP1039903A4 (en)
JP (1) JP2002509105A (en)
AU (1) AU2234199A (en)
CA (1) CA2318195A1 (en)
WO (1) WO1999036069A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR008331A1 (en) * 1997-01-23 1999-12-29 Smithkline Beecham Corp ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PE20011124A1 (en) 2000-03-31 2001-10-28 Upjohn Co NEW BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS
DE10038709A1 (en) * 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituted and unsubstituted benzooxathiazoles and compounds derived from them
AU2003221184A1 (en) * 2002-03-29 2003-10-27 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
MY143477A (en) 2002-10-29 2011-05-31 Smithkline Beecham Corp Il-8 receptor antagonists
JP2009534420A (en) 2006-04-21 2009-09-24 スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
CN101472477B (en) 2006-04-21 2013-02-20 史密丝克莱恩比彻姆公司 IL-8 receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049286A1 (en) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3302125A1 (en) * 1983-01-22 1984-07-26 Boehringer Ingelheim KG, 6507 Ingelheim AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5504095A (en) * 1990-09-19 1996-04-02 Pfizer Inc. Aminobenzosultam derivatives as lipoxygenase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049286A1 (en) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9936069A1 *

Also Published As

Publication number Publication date
EP1039903A4 (en) 2001-12-05
CA2318195A1 (en) 1999-07-22
AU2234199A (en) 1999-08-02
WO1999036069A1 (en) 1999-07-22
JP2002509105A (en) 2002-03-26

Similar Documents

Publication Publication Date Title
AU732728B2 (en) IL-8 receptor antagonists
US5929250A (en) IL-8 receptor antagonists
CA2294064A1 (en) Il-8 receptor antagonists
EP1005341B1 (en) Il-8 receptor antagonists
EP1003497B1 (en) Il-8 receptor antagonists
MXPA01013005A (en) Il-8 receptor antagonists.
EP1039903A1 (en) Il-8 receptor antagonists
US6221889B1 (en) IL-8 receptor antagonists
US6436927B1 (en) IL-8 receptor antagonists
US20030225125A1 (en) IL-8 receptor antagonists
AU767000B2 (en) IL-8 receptor antagonists
WO2000005216A1 (en) Il-8 receptor antagonists
EP1087661A1 (en) Il-8 receptor antagonists
WO2000069435A1 (en) Il-8 receptor antagonists
MXPA01000822A (en) Il-8 receptor antagonists
NZ521057A (en) IL-8 receptor antagonists
MXPA00002283A (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000801

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/41 A, 7C 07D 275/06 B, 7C 07D 513/04 B, 7A 61P 43/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20011022

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020111